Receive The Newest Study Notifications

SELLAS Announces Enrollment of First Patient in Phase 1 Trial of Galinpepimut-S (GPS) in Combination with Nivolumab (Opdivo®) in Patients with Malignant Pleural Mesothelioma (MPM)

by Lance Smith | Feb 12, 2020 | Study Scavenger Clinical Trial Recruitment Platform

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences GroupGroup, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer...

Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease

by Lance Smith | Feb 12, 2020 | Study Scavenger Clinical Trial Recruitment Platform

–  Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease – Patients taking GOCOVRI experienced long-term reductions in both dyskinesia and OFF time sustained for at least two years EMERYVILLE,...

CNS Pharmaceuticals Announces Collaboration with European Partner to Expand Clinical Trials to Pediatric Brain Tumors

by Lance Smith | Feb 12, 2020 | Study Scavenger Clinical Trial Recruitment Platform

HOUSTON, Feb. 11, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced its plan to initiate a...

TLC Announces Early Completion of Patient Enrollment in TLC590 Phase II Clinical Trial following Bunionectomy

by Lance Smith | Feb 12, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Topline results on the analgesic efficacy of TLC590 for postsurgical pain management following the hard tissue surgery are expected in mid-2020 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 12, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a...

T3D Therapeutics Begins Enrollment in the PIONEER Phase 2 Clinical Trial of T3D-959 in Patients with Mild to Moderate Alzheimer’s Disease

by Lance Smith | Feb 12, 2020 | Study Scavenger Clinical Trial Recruitment Platform

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2020 /PRNewswire/ — T3D Therapeutics, Inc. (“T3D” ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD),...

Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer

by Lance Smith | Feb 12, 2020 | Study Scavenger Clinical Trial Recruitment Platform

– After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination – – Findings To Be Presented During an Oral Session at the 2020...